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Peroxisome Proliferator-Activated Receptors at the
rossroads of Obesity, Diabetes, and Cardiovascular Disease
ndries J. Gilde, PHD,*† Jean-Charles Fruchart, PHD,*†‡ Bart Staels, PHD*†‡
ille, France
Since their discovery in the early 1990s, the members of the peroxisome proliferator-activated
receptor (PPAR) subfamily of nuclear receptors have been recognized as therapeutic targets
against dyslipidemia and diabetes. Recent studies also identified anti-inflammatory actions of
PPARs in cells constituting the atherosclerotic lesion. Delineation of this activity extended
the therapeutic potential of PPAR activators beyond their original design as metabolic
controllers. The PPAR family consists of 3 PPAR isoforms: , /, and , which exert
different and sometimes overlapping effects on whole-body physiology in particular on lipid
and glucose metabolism. This review summarizes the current knowledge on the role of
PPARs in cardiovascular disease, the metabolic syndrome, atherosclerosis, and cardiac
function. (J Am Coll Cardiol 2006;48:A24–32) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.04.097Cardiology Foundation
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mn 1990, Issemann and Green (1) discovered the mechanism
y which peroxisome proliferation in the liver was induced
y hypolipidemic drugs and plasticizers (2). This pioneering
esearch paved the way to the current understanding of the
hysiological function of the peroxisome proliferator-
ctivated receptors (PPARs). The PPARs belong to the
uclear receptor superfamily of transcription factors. Since
heir discovery, they have received increasing attention as
otential pharmacologic targets for combating obesity and
iabetes (3). The PPAR family consists of 3 isoforms (i.e.,
PAR, PPAR [also known as ], and PPAR), each
ith their own tissue distribution pattern (4–6). Whereas
PAR is predominantly expressed in tissues with a high
xidative capacity such as the heart and liver, PPAR is
ighest expressed in adipose tissue, and the expression of
PAR/ is more ubiquitous, being highest in skeletal
uscle and intestine. The PPARs can be activated by an
rray of natural (endogenous) ligands, ranging from long-
hain fatty acids to eicosanoids, that all bind with different
ffinity (7–9). In addition, synthetic ligands have been
esigned for the 3 PPAR isoforms with the purpose of
herapeutic application. On ligand-binding, PPARs trans-
ctivate gene expression by heterodimerization with another
ember of the nuclear receptor superfamily, the retinoic X
eceptor, and this complex binds to a direct repeat sequence
esignated PPAR-responsive element (Fig. 1). Alterna-
ively, PPARs are able to down-regulate or transrepress
ene expression via a signal-transduction disrupting mech-
nism independent of DNA binding (10).
CTIONS OF PPAR AGONISTS
PAR. For a long time, the PPAR-activating fibrates
ave been used in the treatment of dyslipidemia. In dyslip-
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ille, and ‡University of Lille 2, Lille, France. Supported by a grant from the
ondation Leducq.w
Manuscript received November 29, 2005; revised manuscript received April 11,
006, accepted April 18, 2006.demic patients, these drugs improve the plasma lipid profile
y lowering triglyceride, and to a lesser extent, low-density
ipoprotein (LDL) cholesterol levels and by increasing
igh-density lipoprotein (HDL) cholesterol levels. For un-
nown reasons, the HDL-increasing effect of fibrates seems
ess pronounced in type 2 diabetic patients (11,12). These
ffects are achieved by a variety of mechanisms, such as an
ncrease in lipoprotein lipase expression, reduction of
polipoprotein (apo)CIII expression, inhibition of triglyc-
ride synthesis, and very-low-density lipoprotein produc-
ion. Furthermore, fibrates increase the expression of fatty
cid metabolizing genes in oxidative tissues, resulting in an
ncreased oxidation of fatty acids (reviewed by Chinetti-
baguidi et al. [13]). Treatment of hyperlipidemia to
educe the risk of cardiovascular disease (CVD) has focused
redominantly on LDL cholesterol-lowering strategies,
ainly by use of statins (14). However, several large studies
ave shown that the use of PPAR-activating drugs is
avorable in the reduction of CVD risk factors, as summa-
ized by the FIELD (Fenofibrate Intervention and Event
owering in Diabetes) investigators (15). Furthermore, it
as shown that PPAR agonists prevented the progression
f arterial lumen occlusion, reduced the incidence of myo-
ardial infarction, and reduced cardiovascular events
11,12,16–23) (Table 1). Apart from the abovementioned
ffects, PPAR activators favorably affect CVD by influ-
ncing atherosclerotic plaque composition (24). Recently it
as shown that PPAR is expressed in cell types involved in
he process of atherosclerosis. This enables this isoform to
ffect this process at the cellular level independent of or in
ddition to acting via blood lipid changes. PPAR activa-
ion reduces the infiltration of macrophages into the ath-
rosclerotic plaque, reduces intraplaque lipid accumulation
n an animal model of mixed dyslipidemia, and reduces
holesterol esterification in human macrophages caused by
n increased adenosine triphosphate-binding cassette A1–
ediated cholesterol efflux (24,25). Furthermore, fibrates
ere shown to reduce the production of proinflammatory
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November 7, 2006:A24–32 PPAR in Cardiovascular Diseaseytokines such as interleukin (IL)-6, interferon , tumor
ecrosis factor , IL-1, and high-sensitivity C-reactive
rotein that may contribute to reducing the risk of cardio-
ascular events (10,25–27). Recently it was discovered that
PAR is regulating cell-cycle genes and cell proliferation
f vascular smooth muscle cells, implying that this nuclear
eceptor is a therapeutic target in restenosis after coronary
ngioplasty (10,28).
One of the few potentially undesirable effects reported on
brate use is the increase of plasma homocysteine that
ccurs via a PPAR-dependent mechanism (29). However,
he clinical consequences of these findings are debatable
ecause the increase of homocysteine levels caused by
enofibrate had no effect on the reduction of vessel lumen
iameter or clinical events in DAIS (Diabetes Atheroscle-
osis Intervention Study) (30). A recent study suggested that
omocysteine could reduce hepatic apoAI production, at
east in part, by decreasing PPAR activity (31). Whether
his mechanism may participate in the lack of effect of
enofibrate on apoAI in type 2 diabetic patients as observed
n the recently published the FIELD (Fenofibrate Interven-
ion and Event Lowering in Diabetes) trial (12) remains to
e established.
Recently, emotions have risen by the reports of rhabdo-
yolysis as a result of the use of statins in combination with
PAR agonists (32,33). Close review of the literature
howed an increased risk only on gemfibrozil use, but not
ith fenofibrate (34). Gemfibrozil is believed to alter statin
etabolism, resulting in increased statin plasma levels (35).
he risk of rhabdomyolysis was greatly reduced by using
ower concentrations of statins or combining other fibrates
han gemfibrozil with other statins than cerivastatin, which
as removed from the market (36,37). The recent FIELD
tudy showed no adverse effects of the combined use of
tatins with fenofibrate (12).
PAR/. Exciting new developments were reported in
he field of PPAR/ research. This isoform has long been
he neglected PPAR isoform because it is ubiquitously
xpressed, making it difficult to pinpoint ligand-mediated
ffects to specific tissues. With the development and use of
ompounds such as L165041, GW501516, and GW610742
ata concerning PPAR/ function in (patho)physiology is
ccumulating (38). In several animal models of obesity and
iabetes, it was shown that these compounds increase HDL
Abbreviations and Acronyms
CVD  cardiovascular disease
HDL  high-density lipoprotein
IL  interleukin
LDL  low-density lipoprotein
PPAR  peroxisome proliferator-activated receptors
SPPARM  selective peroxisome proliferator-activated
receptors modulator
TZD  thiazolidinedioneholesterol and decrease white adipose tissue fat deposits,
*
priglycerides, fasting insulin, and small-density LDL, sug-
esting PPAR/ to be a suitable target in hyperlipidemia
39,40). Additionally, it was discovered that PPAR/
ctivates fatty acid oxidation in heart and skeletal muscle by
ncreasing the expression of genes involved in fatty acid
andling and changing skeletal muscle fiber type from
lycolytic to oxidative (41). Altogether these studies suggest
hat PPAR/ is a promising new target in the battle
gainst obesity and diabetes and subsequent CVD. Exten-
ive research into the function of this isoform in body
hysiology is warranted, together with safety studies of the
vailable agonists of PPAR/. The latter is important
ecause PPAR/ was found to play a role in cancer in
odents (42–46).
PAR. The thiazolidinediones (TZDs) are PPAR li-
ands in clinical use as insulin sensitizing drugs for the
reatment of type 2 diabetes (47). Preclinical as well as
linical data accumulate on the beneficial effects of TZDs on
VD (Table 1) (48–52). The principal mechanism by
hich TZDs exert their insulin sensitization effect is via the
ctivation of PPAR in adipose tissue, resulting in im-
roved insulin sensitivity in skeletal muscle and liver. By the
nduction of subcutaneous adipocyte differentiation and
ecreasing the visceral-to-subcutaneous adipose tissue ratio,
ZDs help to store free fatty acids in less harmful depots.
he TZDs on the market today are rosiglitazone and
ioglitazone. These compounds have very similar activities,
xcept on plasma lipids, which seem to be more favorably
ffected by pioglitazone (2,53). Although pioglitazone de-
reases triglyceride levels, rosiglitazone is neutral. Both
rugs increase HDL cholesterol, but rosiglitazone treatment
lso increases LDL and total cholesterol levels. The mech-
nism explaining this difference is not yet clear. Although
ome claim pioglitazone to have, albeit limited, PPAR-
ctivating properties, selective peroxisome proliferator-
igure 1. Schematic representation of the transcriptional action of perox-
some proliferator-activated receptors (PPARs) with their heterodimer
artner retinoic X receptor (RXR) and their major physiological functions.
Major function for this isoform but not exclusive. L  ligand; PPRE 
eroxisome proliferator-activated receptor-responsive element.
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PPAR in Cardiovascular Disease November 7, 2006:A24–32ctivated receptors modulator (SPPARM) effects could also
e involved.
In addition to the insulin-sensitizing effect, TZDs pos-
ess anti-inflammatory properties. This, together with the
iscovery that PPAR is expressed in endothelial cells,
acrophages, vascular smooth muscle cells, lymphocytes,
nd platelets, raised the hypothesis that using TZDs could
e a suitable therapeutic approach to combating the devel-
pment and progression of the atherosclerotic plaque (54).
PAR activation results in a decrease of matrix metallo-
roteinase 9 and soluble cluster of differentiation 40–ligand
xpression as well as reduction of plasma IL-6, IL-8,
brinogen, and C-reactive protein levels in both type 2
iabetic and nondiabetic patients (55–58). In addition,
hen added to statin therapy, further atherosclerotic plaque
egression was observed in vivo in rabbits using high-
esolution magnetic resonance imaging (59). The recently
eported PROactive Study (Prospective Pioglitazone Clin-
cal Trial in Macrovascular Events) showed that, although
he primary end point composed of hard CVD, and more
ubjective, procedural end points, was not reached, piogli-
azone significantly decreased the hard end points of CVD
all-cause mortality, nonfatal myocardial infarction, and
troke) (51). A first post-hoc analysis of patients with
yocardial infarction furthermore showed that pioglitazone
ignificantly reduced recurrent cardiovascular events (60).
A notorious effect of TZD use is the gain of weight as a
esult of increased body fat and edema. Although this gain
f weight is paradoxically associated with an improved
able 1. PPAR Agonists in Clinical Trials
PPAR Isoform Ligand Clinical Trial
PAR Fenofibrate DAIS, FIELD*
Gemfibrozil HHS, VA-HIT, LOCAT
PAR Rosiglitazone
Pioglitazone PROactive
anagonist (,/,) Bezafibrate BECAIT, BIP*
No difference in primary end point.
BECAIT  Bezafibrate Coronary Atherosclerosis Intervention Trial; BIP  Bez
isease; DAIS  Diabetes Atherosclerosis Intervention Study; FIELD  Fenofibra
ntima-media thickness; LOCAT  Lopid Coronary Angiography Trial; lumenø
icroalbuminuria; PPAR  peroxisome proliferator-activated receptor; PROac
evascularization; VA-HIT  Veterans Affairs Low-HDL Cholesterol Intervention
able 2. PPAR Polymorphisms and Risk Markers of Cardiovascu
PPAR Isoform Polymorphism
PARA L162V LDL1, apoB1
Intron7 G/C Cardiac hypertr
PARD [294T/C] LDL1
ht1 BMI1, fasting
PARG Pro12Ala BMI2, IR2, s
C161T CAD2, apoB2
Pro115Gln BMI1
Pro467Leu IR1, BP1, TG
Val290Meth IR1, BP1, TG
Arg425Leu DM1, dyslipid
htGTGC Metabolic syndrpoB apolipoprotein B; BMI body mass index; BP blood pressure; CAD coronary
ipoprotein; sBP  systolic blood pressure; TG  triglycerides; TotChol/HDL  ratio oflinical status of the patient, it may be undesirable from a
sychological point of view. Contributing to this weight
ain is the TZD-induced fluid retention partly caused by
PAR-mediated H2O and salt retention in the collecting
uct of the kidney (61). This fluid retention together with
ncreased vascular permeability may result in edema and
ould thus potentially, especially in type 2 diabetic patients
ith diminished cardiac function, precipitate congestive
eart failure (62,63). The recent PROactive Study (51),
nvestigating the use of pioglitazone in diabetic patients
ith macrovascular disease, showed that pioglitazone does
ot increase mortality caused by heart failure.
OLYMORPHISMS AND GENETIC
LTERATIONS OF PPARS AND RISK OF CVD
ariations in the PPAR genes may also modulate the risk
nd susceptibility of disease. The use of animal models
ogether with pharmacologic intervention provided evidence
nderlining the importance of the PPAR family as major
layers in whole-body lipid and glucose homeostasis. These
bservations have been extended by genetic studies in
umans showing that PPARs may influence risk factors of
VD (Table 2).
PARA. Polymorphisms within the human PPAR gene
ave been reported to influence risk markers for CVD
Table 2) (64–68). The L162V polymorphism of PPAR
as identified as a gain of function mutation associated with
avorable differences in plasma lipid concentrations (69).
Risk of CVD References
umenø1, microalb2, MI2, CVD2, revasc2 (12,16,17)
VD2, death2, stroke2, lumenø1, CABG lesions2 (11,18–21)
T2, restenosis2 (48,50)
ortality2, MI2, stroke2 (51)
estenosis2 (52)
umenø1, MI2 (22,23)
e Infarct Prevention; CABG  coronary artery bypass graft; CVD  cardiovascular
rvention and Event Lowering in Diabetes; HHS  Helsinki Heart Study; IMT 
progression of arterial lumen occlusion; MI  myocardial infarction; microalb 
Prospective Pioglitazone Clinical Trial in Macrovascular Events; Revasc 
isease (CVD)
Risk Markers for CVD References
I2, diffuse atherosclerosis2, incidence DM2 (64,65–67)
(68)
(74)
se2 (75)
(80–83)
tChol/HDL2, TG2 (84,85)
(86)
(87,88)
(88)
(89)
(90)L
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R
L
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te Inte
 nolar D
, BM
ophy1
gluco
BP2
, To
1
1
emia1
ome1artery disease; DM diabetes mellitus; IR insulin resistance; LDL low-density
total cholesterol to high-density lipoprotein; other abbreviations as in Table 1.
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November 7, 2006:A24–32 PPAR in Cardiovascular Diseaseurthermore, haplotype analysis showed that the PPAR
ene variation influences the onset of age-related diabetes in
en (64).
In mice, genetic ablation of PPAR not only affects
nergy substrate metabolism by decreasing the ability to
tilize fatty acids, but also impairs the immune system (70).
ecause both mechanisms are involved in the etiology of
VD, these observations strengthen the importance of
PAR in the process of CVD. The recently reported
keletal muscle–specific PPAR transgenic mouse model
eautifully shows the complexity of physiological PPAR
ignaling and the necessary organ crosstalk in this process
71). This study shows an insulin-resistant phenotype in
hese mice. However, (pre)clinical use of fibrates has either
o effect or induces a slight improvement of glucose
etabolism (12,72,73).
PARD. Only recently are data becoming available on
utations or polymorphisms of PPAR/ (Table 2) and
heir influence on body homeostasis or risk of CVD.
kogsberg et al. (74) showed that of the 4 polymorphism
etected in PPAR/, only 294T/C is associated with
ncreased LDL cholesterol levels in healthy subjects. The
are C allele showed higher transcriptional activity at the
romoter level that was partially mediated by an increased
inding of Sp-1. Interestingly, in a Korean population, a
aplotype containing 5 single nucleotide polymorphisms of
PAR/ was associated with a reduction of fasting glucose
evels as well as increased body mass index in healthy
olunteers (75). The clinical consequences of this polymor-
hism are uncertain because both parameters have opposite
ffects on risk for CVD (76). Further studies on PPAR/
olymorphisms are eagerly awaited.
In this respect, the data obtained from genetically altered
ice are of interest. In PPAR/ null mice it was observed
hat gonadal adipose tissue was decreased compared with
ild-type mice, and body weight tended to be decreased
significant in female mice) (77). Interestingly, adipose
issue–specific overexpression of an activated form of
PAR/ also resulted in a reduction of adipose tissue, an
lteration that was shown to be protective against high-fat
eeding (78). Although a function for PPAR/ in energy
xpenditure is established, its influence on atherosclerotic
laque formation or regression is not clear. Whereas an
gonist for PPAR/ did not influence plaque progression,
PAR/ deficiency in macrophages resulted in altered
therosclerosis susceptibility (79).
PARG. Several polymorphisms in the PPAR gene have
een detected (Table 2) (80–90). They have been reported
o influence body mass index, insulin resistance, blood
ressure, and the development of type 2 diabetes. Of special
nterest are the Pro467Leu, Val290Met, and Arg425Leu
utations because these act in a dominant-negative man-
er, resulting in partial lipodystrophy with severe insulin
esistance (87–89). Although these PPAR mutations re-
ult in the increase of risk factors of CVD, they are very rare,
imiting their epidemiologic significance in large population rtudies (81,91–93). Overall we can state that PPAR
utations influence the risk and development of type 2
iabetes.
Comparing the data obtained in human studies with that
rom animal models copying PPAR mutations allows us to
ropose whether polymorphisms in humans either a gain or
loss of function properties. Mice homozygous for PPAR
eficiency or in which the wild-type gene is replaced by a
ominant negative PPAR mutation L466A die in utero at
mbryonic day 10.5 to 11.5 (94). Interestingly heterozygous
PAR knockout mice are more sensitive to insulin during
n oral glucose tolerance test, whereas TZD treatment
ormalized insulin action and high-fat feeding-induced
dipose tissue hypertrophy and insulin resistance in periph-
ral tissues and liver in both wild-type and PPAR /
nimals (95). In addition to these whole-genome transgenic
odels, the tissue-specific knockout models for PPAR
ave proven valuable in delineating the role of this receptor
n specific tissues. Skeletal muscle–specific deletion of
PAR resulted in glucose intolerance and insulin resis-
ance (96,97). Interestingly, only 1 of these models had a
esponse to TZD treatment, further feeding the controversy
round the involvement of muscle in the insulin-sensitizing
ffect of TZDs. Adipose tissue–specific ablation of PPAR
sing the aP2-Cre system was protective against insulin
esistance and body weight gain on high-fat feeding in 1
ase, whereas in a comparable model high-fat feeding
nduced insulin resistance in fat and liver (98,99). Selective
nockout in adipose tissue of the PPAR2 isoform also
esulted in insulin resistance associated with reduced weight
f white but not brown adipose tissue (100). Interestingly,
ntroduction of the Pro12Ala mutation in exon B of the
PAR gene resulted in a reduced expression of both
PAR1 and PPAR2 in white and PPAR2 in brown
dipose tissue (101). These hypomorphic PPAR mice were
ndistinguishable from wild-type littermates at birth, but
ecame growth retarded within the first week after birth,
fter which 24% of the mice died. Furthermore, PPARhyp/
yp mice had less white adipose tissue and normal fasting
lucose and insulin levels, which were elevated in the
ostprandial state compared with those of wild-type litter-
ates. Rosiglitazone treatment only normalized glucose
evels, and insulin levels remained increased. Free fatty acid
evels of PPARhyp/hyp mice were increased and did not
hange on fasting. The lack of adipose tissue in this model
as accompanied by an increased expression in skeletal
uscle of PPAR and PPAR/, together with genes
nvolved in -oxidation.
Altogether the data gathered using tissue-selective
PAR knockout models clearly confirm the role of this
soform in adipose tissue generation and function, but the
etabolic consequences at the whole-body level remain
nclear.
PARs and cardiac function. With the clinical applica-
ion of PPAR activators in type 2 diabetic patients at high
isk of developing CVD, the effects on cardiac function
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PPAR in Cardiovascular Disease November 7, 2006:A24–32ust be considered. Because the heart heavily relies on fatty
cids as a source of energy, it is no surprise that PPAR and
PAR/ play an important role in cardiac physiology.
nterestingly, the absence of PPAR was shown to be
eneficial for cardiac performance after ischemia/
eperfusion injury, whereas cardiac-specific overexpression
f PPAR seemed to be detrimental to cardiac function
102,103). In contrast, several studies showed improved
ardiac function and recovery after ischemia/reperfusion on
PAR activator treatment (104,105). Furthermore, feno-
brate was shown to protect the heart against inflammation
nd fibrosis in an animal hypertension model (106,107). In
n in vitro cardiac-hypertrophy model, the PPAR agonists
enofibrate and Wy-14,643 and the PPAR/ agonist
165041 reduced hypertrophy, although the expression of
oth PPAR and PPAR/ were found to be decreased
uring hypertrophy (108). In contrast, in humans it was
bserved that protein expression of both PPAR and
PAR were increased in failing left ventricle (109).
Cardiomyocyte-specific knockout of PPAR/ resulted
n lipotoxic dilated cardiomyopathy caused by a decreased
xpression of fatty acid handling genes (110). Recently, the
evelopment of a cardiomyocyte-specific PPAR knockout
as shed some light on the role of this PPAR isoform in the
eart and the cardiomyocyte in particular (111). This study
hows PPAR to be a suppressor of nuclear factor (NF)B-
ignaling during growth and development, as can be con-
luded from the development of cardiac hypertrophy in
nockout mice with a concomitant increase of atrial natri-
retic factor expression and increased NFB activity. These
esults substantiate the studies of others who showed car-
ioprotective effects of rosiglitazone via the NFB-pathway
fter cardiac infarction (112,113). Overall, both vascular and
ardiomyocyte-specific activation of all 3 PPAR isoforms
ay prove to be protective in humans. The results of the
ecent PROactive Study are in support of a cardioprotective
ctivity of TZDs in type 2 diabetic patients (51).
EW CONCEPTS AND THERAPEUTIC APPLICATIONS
ithin PPAR research, basic and translational clinical
pproaches resulted in new concepts that can be translated
nd tested into clinical practice in the near future. The
ollowing section of this review discusses some new appli-
ations and new concepts of PPAR biology.
ual PPAR activators. A new class of PPAR activators
re the dual / agonists or glitazars. Combining the
roperties of different PPAR isoforms in 1 drug should yield
ore global effects as compared with isoform-specific ago-
ists. In line with this presumption are the results obtained
rom tesaglitazar-treated rats on a high-fat diet that show
mproved insulin sensitivity, increased non-esterified fatty
cid (NEFA) clearance in white adipose tissue, and in-
reased NEFA use by the liver and skeletal muscle (114).
ecently, clinical data on a dual PPAR/ agonist ap-
eared. In a dose-finding study, the effects of ragaglitazar on Vype 2 diabetic patients was assessed for 12 weeks (115).
agaglitazar reduced fasting plasma glucose levels and
ecreased triglycerides. Furthermore, a decrease was ob-
erved in total and LDL cholesterol, free fatty acids, and
poB, whereas HDL cholesterol was increased. Unfortu-
ately, some adverse effects were reported, such as edema,
nemia, and weight gain. In a multicenter double-blind
lacebo-controlled trial, the effect of the dual PPAR/
gonist muraglitazar (BMS-298585) was tested as mono-
herapy in drug-naïve individuals for 24 weeks (116). The
esults showed a reduction in glycosylated hemoglobin,
riglycerides, total and LDL cholesterol, and apoB. Further-
ore, HDL cholesterol was increased and fasting glucose,
nsulin, and C-peptide levels were decreased, altogether
esults most favorable in reducing the risk of CVD. How-
ver, like PPAR agonists, muraglitazar increases body
eight as well as edema, limiting its clinical dose to 5
g/day, a dose at which the drug likely activates PPAR
redominantly. Furthermore, a recent study suggested that
t the dose of 5 mg/day, muraglitazar increased the inci-
ence of the composite end point consisting of death or
ajor adverse cardiovascular events (myocardial infarction,
troke, transient ischemic attack, and congestive heart fail-
re) as compared with placebo or pioglitazone (117). These
tudies debate the suitability of this PPAR/ agonist for
linical purposes. Compound 23 is a dual PPAR/ activa-
or with triglyceride- and glucose-lowering as well as HDL-
aising properties in zucker diabetic fatty rats (118). Re-
ently, compound T913659 was reported to activate all 3
PAR isoforms (panagonist) with PPAR and PPAR/
s the main targets (119). The T913659 increased HDL
holesterol levels in high-fat-fed St. Kitts Vervet monkeys,
model of nonhuman primate atherosclerosis. In perspec-
ive, bezafibrate, a relatively old fibrate, is a partial agonist
or PPAR, PPAR/, and PPAR, acting thus also as a
anagonist (120). Clinical studies with bezafibrate do not
eport edema or weight gain, promising a new future for
ompounds previously discarded by the industry because of
heir pan-PPAR action.
PPARM. Recently, the concept of the SPPARM was
ntroduced. This concept encompasses the principle of
hemical alteration of PPAR-specific ligands to create com-
ounds that possess differential gene-regulating properties
121). Thus far several compounds have been identified as
PPARMs, some of which are already in clinical testing
Table 3) (122–125). The focus of SPPARM research is
PAR, because the control of adverse effects of PPAR
able 3. Selective PPAR Modulators (SPPARMs) and Their
eported Effects
SPPARM Effects Reference
AT5A Glucose2, TG2, IR2 (122)
TZDpa VSMC proliferation2 (123)
K614 IR2 (124)SMC  vascular smooth muscle cell; other abbreviations as in Table 2.
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iabetes.
onclusions. This review highlights the different levels at
hich the members of the PPAR family affect obesity,
iabetes, and cardiovascular disease. The current publication
ate on this topic is illustrative of the interest in this field.
he combined efforts of basic and clinical science together
ith pharmaceutical developments resulted in the discovery
f many new pathways, treatment strategies, and drugs of
otential interest for the treatment of obesity, diabetes, and
ardiovascular disease.
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